Categories: News

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences:

  • One-on-one and small group meetings at the 19th Annual Craig-Hallum Institutional Investor Conference (virtual) on Wednesday, June 1, 2022; and
  • A fireside chat at the Jefferies Healthcare Conference in New York at 2:30 p.m. ET on Thursday, June 9, 2022. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff240/celc/1811175. Alternatively, the live webcast will be accessible from the Investors section of the company’s website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.

About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company’s lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

CONTACT
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/702798/Celcuity-to-Participate-in-Upcoming-Craig-Hallum-and-Jefferies-Investor-Conferences

Staff

Recent Posts

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

2 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

2 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

2 hours ago

Calm Nature CBD Gummies Ingredients: 2026 Consumer Analysis Examines Full Spectrum CBD Claims, Testing Standards, and Formulation Transparency

Independent report examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, THC removal…

2 hours ago